Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Gilead had been the darling of investors a ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Gilead Sciences, and Apellis Pharmaceuticals. According to TipRanks, Stringer has an average return of 7.5% ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today. The company’s ...

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.